Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
Pemafibrate (K-877) is a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα) with a favorable benefit-risk balance. Previous clinical trials of pemafibrate used stringent exclusion criteria related to renal functions. Therefore, we investigated its safety and efficacy in...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/3/706 |
id |
doaj-e5f59f31f35d449887ec9dd60c22c48f |
---|---|
record_format |
Article |
spelling |
doaj-e5f59f31f35d449887ec9dd60c22c48f2020-11-25T00:27:20ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-02-0120370610.3390/ijms20030706ijms20030706Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal ImpairmentKoutaro Yokote0Shizuya Yamashita1Hidenori Arai2Eiichi Araki3Hideki Suganami4Shun Ishibashi5on Behalf of the K-877 Study GroupDepartment of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba 260-8670, JapanDepartment of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanNational Center for Geriatrics and Gerontology, Aichi 474-8511, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, JapanClinical Data Science Department, Kowa Company, Ltd., Tokyo 103-8433, JapanDivision of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, Tochigi 329-0498, JapanPemafibrate (K-877) is a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα) with a favorable benefit-risk balance. Previous clinical trials of pemafibrate used stringent exclusion criteria related to renal functions. Therefore, we investigated its safety and efficacy in a broader range of patients, including those with chronic kidney disease (CKD). In this multicenter, single-arm, open-label, phase III trial, 0.2–0.4 mg/day pemafibrate was administered for 52 weeks to 189 patients with hypertriglyceridemia and an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m<sup>2</sup> on statin or regardless of eGFR when statin was not administered. Post-hoc analyses were performed on subgroups stratified by baseline eGFR. Triglyceride levels decreased by 45.9% at week 52 (last-observation-carried-forward). These reductions were not correlated with baseline eGFR. The eGFR < 30 mL/min/1.73 m<sup>2</sup> subgroup showed the greatest reduction in chylomicron, very low-density lipoprotein, small low-density lipoprotein cholesterol levels, and an increase in high-density lipoprotein cholesterol levels. The incidences of adverse events and adverse drug reactions were 82.0% and 31.7%, respectively, and these were not associated with baseline eGFR. In CKD patients, pemafibrate blood concentrations were not elevated. Pemafibrate showed a good safety profile and efficacy in correcting lipid abnormalities in a broad range of patients, including those with CKD.https://www.mdpi.com/1422-0067/20/3/706high-density lipoprotein cholesterolK-877pemafibraterenal dysfunctionsafetyselective PPARα modulatortriglyceride |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Koutaro Yokote Shizuya Yamashita Hidenori Arai Eiichi Araki Hideki Suganami Shun Ishibashi on Behalf of the K-877 Study Group |
spellingShingle |
Koutaro Yokote Shizuya Yamashita Hidenori Arai Eiichi Araki Hideki Suganami Shun Ishibashi on Behalf of the K-877 Study Group Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment International Journal of Molecular Sciences high-density lipoprotein cholesterol K-877 pemafibrate renal dysfunction safety selective PPARα modulator triglyceride |
author_facet |
Koutaro Yokote Shizuya Yamashita Hidenori Arai Eiichi Araki Hideki Suganami Shun Ishibashi on Behalf of the K-877 Study Group |
author_sort |
Koutaro Yokote |
title |
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment |
title_short |
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment |
title_full |
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment |
title_fullStr |
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment |
title_full_unstemmed |
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment |
title_sort |
long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator (spparmα), in dyslipidemic patients with renal impairment |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-02-01 |
description |
Pemafibrate (K-877) is a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα) with a favorable benefit-risk balance. Previous clinical trials of pemafibrate used stringent exclusion criteria related to renal functions. Therefore, we investigated its safety and efficacy in a broader range of patients, including those with chronic kidney disease (CKD). In this multicenter, single-arm, open-label, phase III trial, 0.2–0.4 mg/day pemafibrate was administered for 52 weeks to 189 patients with hypertriglyceridemia and an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m<sup>2</sup> on statin or regardless of eGFR when statin was not administered. Post-hoc analyses were performed on subgroups stratified by baseline eGFR. Triglyceride levels decreased by 45.9% at week 52 (last-observation-carried-forward). These reductions were not correlated with baseline eGFR. The eGFR < 30 mL/min/1.73 m<sup>2</sup> subgroup showed the greatest reduction in chylomicron, very low-density lipoprotein, small low-density lipoprotein cholesterol levels, and an increase in high-density lipoprotein cholesterol levels. The incidences of adverse events and adverse drug reactions were 82.0% and 31.7%, respectively, and these were not associated with baseline eGFR. In CKD patients, pemafibrate blood concentrations were not elevated. Pemafibrate showed a good safety profile and efficacy in correcting lipid abnormalities in a broad range of patients, including those with CKD. |
topic |
high-density lipoprotein cholesterol K-877 pemafibrate renal dysfunction safety selective PPARα modulator triglyceride |
url |
https://www.mdpi.com/1422-0067/20/3/706 |
work_keys_str_mv |
AT koutaroyokote longtermefficacyandsafetyofpemafibrateanovelselectiveperoxisomeproliferatoractivatedreceptoramodulatorspparmaindyslipidemicpatientswithrenalimpairment AT shizuyayamashita longtermefficacyandsafetyofpemafibrateanovelselectiveperoxisomeproliferatoractivatedreceptoramodulatorspparmaindyslipidemicpatientswithrenalimpairment AT hidenoriarai longtermefficacyandsafetyofpemafibrateanovelselectiveperoxisomeproliferatoractivatedreceptoramodulatorspparmaindyslipidemicpatientswithrenalimpairment AT eiichiaraki longtermefficacyandsafetyofpemafibrateanovelselectiveperoxisomeproliferatoractivatedreceptoramodulatorspparmaindyslipidemicpatientswithrenalimpairment AT hidekisuganami longtermefficacyandsafetyofpemafibrateanovelselectiveperoxisomeproliferatoractivatedreceptoramodulatorspparmaindyslipidemicpatientswithrenalimpairment AT shunishibashi longtermefficacyandsafetyofpemafibrateanovelselectiveperoxisomeproliferatoractivatedreceptoramodulatorspparmaindyslipidemicpatientswithrenalimpairment AT onbehalfofthek877studygroup longtermefficacyandsafetyofpemafibrateanovelselectiveperoxisomeproliferatoractivatedreceptoramodulatorspparmaindyslipidemicpatientswithrenalimpairment |
_version_ |
1725340639274467328 |